Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.

For many metastatic cancer patients, a one-time whole-genome analysis of a biopsy may be enough to identify their treatment options, a new study has found.

Castle Biosciences reported after the close of the market on Monday that its first quarter revenues rose 79 percent year over year, thanks to more than double the number of tests delivered during the quarter.

Quidel reported after the close of the market Thursday that its second quarter revenues fell 12 percent year over year, which the firm attributed to decreased demand for its Sofia and PCR COVID-19 assays, as well as lower demand for influenza products.

Meridian Bioscience reported on Friday morning a 25 percent year-over-year decline in its fiscal third quarter revenues, one year after recording record highs in Q3 2020.

A newly finalized guidance from the US Food and Drug Administration (FDA) helps manufacturers understand how to use near-infrared (NIR)-based analyses in evaluating drug attributes.

Sansure biology and Zhuhai Baolian signed the termination agreement of the share transfer agreement on August 5, 2021.

2021 ranking features 143 Chinese companies, 122 U.S. companies, and 53 Japanese companies. 6 in vitro diagnostic companies on the list.

On August 3, Sinopharm listed its 30% equity interest in Maixin Biotechnology on the China Beijing Equity Exchange at a price of 947.5 million yuan. Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) said they would fight for the acquisition.

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.

On July 28, 2021, Thermo Fisher Scientific announcing that it would invest in the construction of another brand-new factory under Thermo Fisher China manufacturing center in Suzhou High Tech Zone. The total investment is $50 million, which is expected to be completed and put into use in 2022.

PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021.

On July 25, 2021, Autobio and Syscan officially announced the launch of a strategic cooperation. In the future, the two companies will make full use of their respective technology and channel advantages to carry out a full range of in-depth cooperation in the field of coagulation testing.

July 22, Roche reported a 51 percent increase in half-year revenues for its Diagnostics division, largely thanks to demand for its COVID-19 products.